Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Compassion-Based Family Intervention for Adolescents

NCT07138417 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2025-08-30
Last updated
2026-09-30

Condition(s) studied

Emotional Disorder

Investigational drug(s) / intervention(s)

Compassion-Based Family Intervention

Compassion-Based Family Intervention: A 6-week program (120 minutes weekly) combining theoretical content and group activities, with additional home practice (emotion diaries and meditation). Content focuses on cultivating self-compassion and compassion for others, developing inward awareness and outward observation, improving perspective-taking and communication skills, and managing conflict within the family. Weekly themes: Week 1 "Setting Sail Together, Understanding Love in Thought and Action"; Week 2 "Inward Awareness, Resonance of Body and Mind"; Week 3 "Outward Observation, Seeing One Another Clearly"; Week 4 "Shifting Perspectives, Bridging Boundaries"; Week 5 "Perspective-Taking, Managing Conflict"; Week 6 "Harnessing Compassion, Bringing Love Home."

Study summary

Adolescents with emotional disorders often experience psychological distress that may also affect their parents, creating bidirectional stress within the family. This randomized waitlist-controlled trial will evaluate a 6-week compassion-based family intervention involving adolescents and their parents. A total of 60 parent-adolescent dyads will be randomly assigned to either an intervention group or a waitlist control group. The primary outcomes are adolescents' depressive and anxiety symptoms. Secondary outcomes include broader psychological and family-related measures. Parent-child neural and physiological synchrony will also be explored using fNIRS hyperscanning and wearable devices. Assessments will be conducted at baseline, post-intervention, and 3-month and 6-month follow-ups.

Eligibility

Sex
ALL
Min age
12 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * the adolescent is aged 12-18 years * for the adolescent, required scores at enrollment: at least one of the following criteria is met (i) 17-item Hamilton Depression Rating Scale (HAMD-17) (Hamilton, 1960) total score ≥17 and ≤30, (ii) Hamilton Anxiety Rating Scale (HAMA) (Hamilton, 1959) total score ≥18 and ≤29; and in addition, the HAMD-17 item 3 (suicide) score must be ≤ 2 * at least one parent is willing to participate * the adolescent has normal auditory and visual perception abilities and intellectual functioning * the participating parent has normal reading and writing ability * the adolescent has no history of manic episodes Exclusion Criteria: * the adolescent presents with psychotic symptoms, bipolar disorder, or schizophrenia * the parent suffers from a mental illness or psychological disorder * the adolescent or their parent has a history of substance abuse * the adolescent or their parent has a severe neurological disorder or major physical disease * the adolescent or their parent is assessed as having high suicide risk

Primary outcome measure(s)

  • Children's depression levels — baseline, immediately after the intervention, and 3, 6 month follow-up
    Children's depression levels will be assessed using the Children's Depression Inventory (CDI). The total score of 27 items will be calculated, with each item scored from 0 to 2. Higher scores indicate more severe depressive symptoms.
  • Children's anxiety levels — baseline, immediately after the intervention, and 3, 6 month follow-up
    Children's anxiety levels will be assessed using the Beck Anxiety Inventory (BAI). The total score of 21 items will be calculated, with each item scored from 0 to 3. Higher scores indicate more severe anxiety.

Trial sites (1)

FacilityCityRegionStatus
Hefei Fourth People's Hospital (Anhui Mental Health Center; Affiliated Psychological Hospital of Anhui Medical University) Hefei Anhui Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07138417 on ClinicalTrials.gov ↗ ← All trials in China